OncoCyte Corporation

NasdaqCM OCX

OncoCyte Corporation Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

OncoCyte Corporation Interest Coverage Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

OncoCyte Corporation Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -612.07.
OncoCyte Corporation Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -171.81, a -235.26% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: OCX

OncoCyte Corporation

CEO	Mr. Joshua Riggs
IPO Date	Dec. 30, 2015
Location	United States
Headquarters	15 Cushing
Employees	43
Sector	Healthcare
Industries Biotechnology

Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Key trends

Past 5 years